← Browse by Condition
Medical Condition
myelodysplastic syndromes
Total Trials
22
Recruiting Now
22
Trial Phases
Phase 2, Phase 1, EARLY_Phase 1
NCT05875805
Recruiting
A Telehealth Advance Care Planning Intervention
Enrollment
207 pts
Location
United States
Sponsor
University of Rochester
NCT06956755
Recruiting
Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia
Enrollment
6,990 pts
Location
France
Sponsor
Groupe Francophone des Myelody...
NCT07238686 Phase 2
Recruiting
Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS
Enrollment
40 pts
Location
China
Sponsor
Beijing 302 Hospital
NCT06501196 Phase 1
Recruiting
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Enrollment
170 pts
Location
United States
Sponsor
BlossomHill Therapeutics
NCT05184842 Phase 2
Recruiting
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Enrollment
91 pts
Location
United States
Sponsor
Montefiore Medical Center
NCT05805605 Phase 2
Recruiting
Allo HSCT Using RIC and PTCy for Hematological Diseases
Enrollment
56 pts
Location
United States
Sponsor
Masonic Cancer Center, Univers...
NCT06379945
Recruiting
Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA)
Enrollment
300 pts
Location
Spain
Sponsor
Instituto de Investigación Bio...
NCT06113302 Phase 2
Recruiting
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
Enrollment
40 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT04187703 EARLY_Phase 1
Recruiting
5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
Enrollment
20 pts
Location
United States
Sponsor
Benjamin Tomlinson
NCT05588154
Recruiting
Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies
Enrollment
1,000 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
NCT05365035 Phase 2
Recruiting
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
Enrollment
60 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT05807932 Phase 1, Phase 2
Recruiting
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Enrollment
38 pts
Location
Germany
Sponsor
Heinrich-Heine University, Due...
NCT06297941 Phase 1
Recruiting
Study of REM-422 in Patients With AML or Higher Risk MDS
Enrollment
100 pts
Location
United States, Franc...
Sponsor
Remix Therapeutics
NCT05194397 Phase 2
Recruiting
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
Enrollment
80 pts
Location
United States
Sponsor
Children's Hospital of Philade...
NCT04587856
Recruiting
Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients
Enrollment
38 pts
Location
Italy
Sponsor
Gruppo Italiano Malattie EMato...
NCT06594445 Phase 1
Recruiting
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
Enrollment
45 pts
Location
United States
Sponsor
Masonic Cancer Center, Univers...
NCT04678401 Phase 1
Recruiting
IS-free Treg HaploHCT
Enrollment
30 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
NCT03291444 Phase 1
Recruiting
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
Enrollment
30 pts
Location
China
Sponsor
Zhujiang Hospital
NCT00935090
Recruiting
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Location
United States
Sponsor
Barbara Ann Karmanos Cancer In...
NCT03275480
Recruiting
Institut Paoli Calmettes Myelodysplastic Syndromes Database
Enrollment
10,000 pts
Location
France
Sponsor
Institut Paoli-Calmettes
NCT04953897 Phase 1
Recruiting
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Enrollment
18 pts
Location
United States, Armen...
Sponsor
Taiho Oncology, Inc.
NCT06303193 Phase 1, Phase 2
Recruiting
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Enrollment
160 pts
Location
United States
Sponsor
National Cancer Institute (NCI...